

Please type a plus sign (+) inside this box →

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3

of

Complete If Known

Application Number	09/905,439
Filing Date	July 13, 2001
First Named Inventor	Doetsch, Volker
Group Art Unit	1645
Examiner Name	

Attorney Docket Number 023070-119400US

DEC 13 2001

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
88	AA	5,817,474		Brown	10/06/98	_____
88	AB	5,922,545		Mattheakis, et al.	07/13/99	_____
88	AC	6,111,066		Anderson, III, et al.	08/29/00	_____
88	AD	6,133,736		Pervushin, et al.	10/17/00	_____
88	AE	6,214,561 B1		Peters, et al.	04/10/01	_____

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	AF							
	AG							

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
88	AH	Bachert, "Pharmacokinetics Using Fluorine NMR in Vivo," <u>Prog. Nucl. Magn. Reson. Spectr.</u> , 33:1-56 (1998).	_____
88	AI	Elowitz et al., "Protein Mobility in the Cytoplasm of Escherichia Coli," <u>J. Bact.</u> , 181(1):197-203 (1999).	_____
88	AJ	Flynn and Wand, "High-Resolution Nuclear Magnetic Resonance of Encapsulated Proteins Dissolved in Low Viscosity Fluids," <u>Meth. Enzymol.</u> , 339:54-70 (2001).	_____
88	AK	Gronenborn and Clore, "Rapid Screening for Structural Integrity of Expressed Proteins by Heteronuclear NMR Spectroscopy," <u>Prot. Sci.</u> , 5:174-177 (1996).	_____
88	AL	Henklein, et al., "Functional and Structural Characterization of Synthetic HIV-1 Vpr That Transduces Cells, Localizes to the Nucleus, and Induces G ₂ Cell Cycle Arrest," <u>J. Biol. Chem.</u> , 275(41):32016-32026 (10/13/00).	_____
88	AM	Kanamori and Ross, "Glial Alkalization Detected in Vivo by ¹ H- ¹⁵ N Heteronuclear Multiple-Quantum Coherence-Transfer NMR in Severely Hyperammonemic Rat," <u>J. Neurochem.</u> , 68(3):1209-1220 (1997).	_____
88	AN	Li et al., "Molar Quantitation of Hepatic Metabolites in Vivo in Proton-Decoupled, Nuclear Overhauser Effect Enhanced ³¹ P NMR Spectra Localized by Three-Dimensional Chemical Shift Imaging," <u>NMR Biomed.</u> , 9:141-155 (1996).	_____

Examiner Signature

Patience A. Babel

Date Considered

2/11/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments or the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1297551 v1

Please type a plus sign (+) inside this box → +

DEC 13 2001

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4

of

Complete If Known

Application Number	09/905,439
Filing Date	July 13, 2001
First Named Inventor	Doetsch, Volker
Group Art Unit	1645
Examiner Name	

Attorney Docket Number 023070-119400US

TECH CENTER 1600/2800

RECEIVED
DEC 26 2001

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
88	AO	Serber et al., "High-Resolution Macromolecular NMR Spectroscopy Inside Living Cells," <u>J. Am. Chem. Soc.</u> , 123:2446-2447 (2001).						1
88	AP	Spindler et al., "Altered Creatine Kinase Enzyme Kinetics in Diabetic Cardiomyopathy. A 31P NMR Magnetization Transfer Study of the Intact Beating Rat Heart," <u>J. Mol. Cell. Cardiol.</u> , 31:2175-2189 (1999).						1
88	AQ	Williams et al., "F NMR Measurements of the Rotational Mobility of Proteins in Vivo," <u>Biophys. J.</u> , 72:490-498 (1997).						1
	AR							

Examiner Signature	<i>Barbara A. Dahl</i>	Date Considered	2/11/03
--------------------	------------------------	-----------------	---------

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case: Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1297551 v1